ICON Public Limited Company (ICLR)
USD 146.74
(1.87%)
USD 146.74
(1.87%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.66 Billion USD | -22.52% |
| 2022 | 4.73 Billion USD | -14.62% |
| 2021 | 5.54 Billion USD | 1253.76% |
| 2020 | 409.27 Million USD | 434.35% |
| 2019 | 76.59 Million USD | -78.07% |
| 2018 | 349.26 Million USD | 0.11% |
| 2017 | 348.88 Million USD | 0.11% |
| 2016 | 348.51 Million USD | -0.43% |
| 2015 | 350 Million USD | 26.84% |
| 2014 | 275.94 Million USD | 30.6% |
| 2013 | 211.28 Million USD | 2758.32% |
| 2012 | 7.39 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 65.65 Million USD | 28.46% |
| 2007 | 51.11 Million USD | 31256.44% |
| 2006 | 163 Thousand USD | 7.24% |
| 2005 | 152 Thousand USD | -38.71% |
| 2004 | 248 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 253 Thousand USD | -70.51% |
| 2000 | 858 Thousand USD | 71.6% |
| 1999 | 500 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 3.41 Billion USD | -6.7% |
| 2024 Q3 | 3.4 Billion USD | -0.17% |
| 2024 Q2 | 3.4 Billion USD | -0.34% |
| 2023 Q2 | 4.33 Billion USD | -3.36% |
| 2023 FY | 3.66 Billion USD | -22.52% |
| 2023 Q1 | 4.48 Billion USD | -5.16% |
| 2023 Q4 | 3.66 Billion USD | -9.11% |
| 2023 Q3 | 4.03 Billion USD | -6.99% |
| 2022 Q3 | 4.92 Billion USD | -4.21% |
| 2022 FY | 4.73 Billion USD | -14.62% |
| 2022 Q1 | 5.24 Billion USD | -5.4% |
| 2022 Q2 | 5.13 Billion USD | -1.97% |
| 2022 Q4 | 4.73 Billion USD | -3.87% |
| 2021 FY | 5.54 Billion USD | 1253.76% |
| 2021 Q1 | 400.77 Million USD | -2.08% |
| 2021 Q2 | 397.33 Million USD | -0.86% |
| 2021 Q3 | 6.06 Billion USD | 1426.08% |
| 2021 Q4 | 5.54 Billion USD | -8.62% |
| 2020 Q2 | 63.97 Million USD | -14.43% |
| 2020 Q1 | 74.75 Million USD | -2.39% |
| 2020 Q3 | 62.49 Million USD | -2.31% |
| 2020 Q4 | 409.27 Million USD | 554.91% |
| 2020 FY | 409.27 Million USD | 434.35% |
| 2019 Q4 | 76.59 Million USD | -82.14% |
| 2019 FY | 76.59 Million USD | -78.07% |
| 2019 Q3 | 428.95 Million USD | -0.02% |
| 2019 Q1 | 432.52 Million USD | 23.84% |
| 2019 Q2 | 429.02 Million USD | -0.81% |
| 2018 Q1 | 348.98 Million USD | 0.03% |
| 2018 FY | 349.26 Million USD | 0.11% |
| 2018 Q4 | 349.26 Million USD | 0.03% |
| 2018 Q3 | 349.16 Million USD | 0.03% |
| 2018 Q2 | 349.07 Million USD | 0.03% |
| 2017 Q1 | 348.6 Million USD | 0.03% |
| 2017 FY | 348.88 Million USD | 0.11% |
| 2017 Q4 | 348.88 Million USD | 0.03% |
| 2017 Q3 | 348.79 Million USD | 0.03% |
| 2017 Q2 | 348.69 Million USD | 0.03% |
| 2016 FY | 348.51 Million USD | -0.43% |
| 2016 Q1 | 348.27 Million USD | -0.49% |
| 2016 Q2 | 348.32 Million USD | 0.01% |
| 2016 Q3 | 401.41 Million USD | 15.24% |
| 2016 Q4 | 348.51 Million USD | -13.18% |
| 2015 Q3 | 11.92 Million USD | 2.99% |
| 2015 FY | 350 Million USD | 26.84% |
| 2015 Q2 | 11.58 Million USD | -2.7% |
| 2015 Q1 | 11.9 Million USD | -95.69% |
| 2015 Q4 | 350 Million USD | 2834.52% |
| 2014 Q3 | 3.89 Million USD | 15.73% |
| 2014 FY | 275.94 Million USD | 30.6% |
| 2014 Q1 | 2.94 Million USD | -98.61% |
| 2014 Q4 | 275.94 Million USD | 6988.16% |
| 2014 Q2 | 3.36 Million USD | 14.15% |
| 2013 Q2 | 8.23 Million USD | 26.03% |
| 2013 FY | 211.28 Million USD | 2758.32% |
| 2013 Q4 | 211.28 Million USD | 3387.74% |
| 2013 Q3 | 6.05 Million USD | -26.44% |
| 2013 Q1 | 6.53 Million USD | -26.94% |
| 2012 FY | 7.39 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | 8.94 Million USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q2 | 31.04 Million USD | -49.4% |
| 2009 FY | - USD | -100.0% |
| 2009 Q1 | 61.36 Million USD | -6.54% |
| 2009 Q3 | 25.93 Million USD | -16.47% |
| 2009 Q4 | - USD | -100.0% |
| 2008 Q2 | 48.4 Million USD | 0.01% |
| 2008 Q3 | 37.56 Million USD | -22.38% |
| 2008 FY | 65.65 Million USD | 28.46% |
| 2008 Q1 | 48.39 Million USD | -5.32% |
| 2008 Q4 | 65.65 Million USD | 74.76% |
| 2007 FY | 51.11 Million USD | 31256.44% |
| 2007 Q1 | 138 Thousand USD | -15.34% |
| 2007 Q4 | 51.11 Million USD | 72915.71% |
| 2007 Q3 | 70 Thousand USD | -36.36% |
| 2007 Q2 | 110 Thousand USD | -20.29% |
| 2006 Q1 | 123 Thousand USD | -25.45% |
| 2006 FY | 163 Thousand USD | 7.24% |
| 2006 Q3 | 193 Thousand USD | 93.0% |
| 2006 Q4 | 163 Thousand USD | -15.54% |
| 2006 Q2 | 100 Thousand USD | -18.7% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | 152 Thousand USD | -38.71% |
| 2005 Q4 | 165 Thousand USD | -19.12% |
| 2005 Q3 | 204 Thousand USD | -17.74% |
| 2005 Q2 | 248 Thousand USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | 248 Thousand USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q1 | 297 Thousand USD | -60.19% |
| 2001 Q4 | - USD | -100.0% |
| 2001 FY | 253 Thousand USD | -70.51% |
| 2001 Q3 | 240 Thousand USD | -5.14% |
| 2001 Q2 | 253 Thousand USD | -14.81% |
| 2000 Q1 | 940 Thousand USD | 135.0% |
| 2000 Q4 | 746 Thousand USD | -9.9% |
| 2000 Q3 | 828 Thousand USD | -3.5% |
| 2000 Q2 | 858 Thousand USD | -8.72% |
| 2000 FY | 858 Thousand USD | 71.6% |
| 1999 Q4 | 400 Thousand USD | 0.0% |
| 1999 FY | 500 Thousand USD | 0.0% |
| 1999 Q2 | 500 Thousand USD | 0.0% |
| 1999 Q3 | 400 Thousand USD | -20.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aspira Women's Health Inc. | 1.43 Million USD | -256224.406% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | -327619.613% |
| Intelligent Bio Solutions Inc. | 81.32 Thousand USD | -4507104.515% |
| Standard BioTools Inc. | 3.98 Million USD | -91927.09% |
| Inotiv, Inc. | 399.4 Million USD | -817.716% |
| Prenetics Global Limited | 867.21 Thousand USD | -422567.851% |
| Neuronetics, Inc. | 59.28 Million USD | -6082.951% |
| Star Equity Holdings, Inc. | 1.14 Million USD | -320025.677% |
| Castle Biosciences, Inc. | 14.19 Million USD | -25716.587% |
| Psychemedics Corporation | 945 Thousand USD | -387777.143% |
| RadNet, Inc. | 812.06 Million USD | -351.371% |
| Exact Sciences Corporation | 2.47 Billion USD | -48.078% |
| IDEXX Laboratories, Inc. | 622.88 Million USD | -488.463% |
| iSpecimen Inc. | 29.13 Thousand USD | -12582938.105% |
| OpGen, Inc. | 2.02 Million USD | -181212.326% |
| Exagen Inc. | 19.23 Million USD | -18960.054% |
| Bionano Genomics, Inc. | 7.17 Million USD | -50986.258% |
| CareDx, Inc | 28.27 Million USD | -12862.158% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 79.17 Million USD | -4529.658% |
| Guardant Health, Inc. | 1.13 Billion USD | -221.539% |
| Biodesix, Inc. | 35.22 Million USD | -10305.789% |
| BioNexus Gene Lab Corp. | 98.76 Thousand USD | -3711248.379% |
| Precipio, Inc. | 106 Thousand USD | -3457861.321% |
| Natera, Inc. | 282.94 Million USD | -1195.46% |
| Fulgent Genetics, Inc. | 10.11 Million USD | -36151.993% |
| Sera Prognostics, Inc. | 840 Thousand USD | -436261.786% |
| 23andMe Holding Co. | 67.84 Million USD | -5302.666% |
| OPKO Health, Inc. | 222.03 Million USD | -1550.846% |
| Personalis, Inc. | 1.23 Million USD | -296937.196% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -119140.046% |
| Applied DNA Sciences, Inc. | 739.16 Thousand USD | -495791.158% |
| T2 Biosystems, Inc. | 6.59 Million USD | -55453.789% |
| Neogen Corporation | 888.39 Million USD | -312.593% |
| Myriad Genetics, Inc. | 130.9 Million USD | -2700.183% |
| NeoGenomics, Inc. | 606.06 Million USD | -504.789% |
| Star Equity Holdings, Inc. | 1.14 Million USD | -320025.677% |
| MDxHealth SA | 35.56 Million USD | -10206.599% |
| Prenetics Global Limited | 867.21 Thousand USD | -422567.851% |
| Illumina, Inc. | 1.48 Billion USD | -146.168% |
| DarioHealth Corp. | 24.59 Million USD | -14805.612% |
| ENDRA Life Sciences Inc. | 192.06 Thousand USD | -1908366.537% |
| Medpace Holdings, Inc. | 142.12 Million USD | -2479.079% |
| Mainz Biomed B.V. | 2.19 Million USD | -166822.782% |
| Trinity Biotech plc | 54.65 Million USD | -6606.993% |
| Sotera Health Company | 2.22 Billion USD | -64.837% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | -327619.613% |